Anthrax vaccine (Trithrax) - Buckler Diodefense

Drug Profile

Anthrax vaccine (Trithrax) - Buckler Diodefense

Alternative Names: Anthrax vaccine (Trithrax) - Virionyx/Zeptometrix; Trithrax

Latest Information Update: 20 May 2008

Price : $50

At a glance

  • Originator Buckler Biodefence Corp
  • Developer Buckler Biodefense
  • Class Anthrax vaccines
  • Mechanism of Action Anthrax toxin inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Clinical Phase Unknown Anthrax

Most Recent Events

  • 11 Jul 2007 This vaccine programme is still in active development
  • 28 Nov 2005 Clinical trials in Anthrax in New Zealand (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top